• Publications
  • Influence
Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo.
Abstract Patients' perspectives concerning the effects of disease and therapy on their lives have become increasingly important for the assessment of medications in clinical trials. The MinnesotaExpand
  • 467
  • 23
Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).
Neuroendocrine activation is known to occur in patients with congestive heart failure, but there is uncertainty as to whether this occurs before or after the presence of overt symptoms. In theExpand
  • 1,366
  • 19
  • PDF
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.
BACKGROUND We conducted a multicenter, placebo-controlled trial designed to establish the efficacy and safety of carvedilol, a "third-generation" beta -blocking agent with vasodilator properties, inExpand
  • 1,233
  • 14
Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion.
We investigated atrial natriuretic factor (ANF) in humans, measuring plasma immunoreactive (ir) ANF (in femtomoles per milliliter), and renal, hormonal, and hemodynamic responses to ANF infusion, inExpand
  • 714
  • 13
  • PDF
Endothelium‐Dependent Vasodilation Is Attenuated in Patients With Heart Failure
BackgroundEndothelial cells produce a number of substances, collectively termed endothelium derived relaxing factor (EDRF), that promote local relaxation of vascular smooth muscle. Although studiesExpand
  • 781
  • 13
Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure.
BACKGROUND Patients with heart failure have reduced peripheral blood flow at rest, during exercise, and in response to endothelium-dependent vasodilators. Nitric oxide formed from L-arginineExpand
  • 273
  • 11
Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial.
BACKGROUND Heart failure (HF) is increasing in prevalence and is a major cause of morbidity and mortality despite advances in medical and device therapy. Autonomic imbalance, with excess sympatheticExpand
  • 152
  • 11
Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection.
Coronary artery disease (CAD) is now the major limitation to long-term survival after cardiac transplantation. Its etiology remains unclear. The possible role of viral infection in the genesis of CADExpand
  • 303
  • 8
Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death.
Treatments for heart failure, such as flosequinan, may have opposite effects on survival and quality of life. The Living With Heart Failure questionnaire was used to examine patients' willingness toExpand
  • 210
  • 8
Liver function abnormalities in chronic heart failure. Influence of systemic hemodynamics.
To characterize the incidence and severity of liver function abnormalities in patients with congestive heart failure, we analyzed systemic hemodynamics and biochemical profiles in 133 patients withExpand
  • 145
  • 7